Welcome to our dedicated page for EyePoint Pharmaceuticals news (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on EyePoint Pharmaceuticals stock.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is a clinical-stage biopharmaceutical company headquartered in Watertown, Massachusetts. The company is committed to developing and commercializing ophthalmic products aimed at treating serious retinal diseases. EyePoint leverages its proprietary Durasert® technology, a sustained intraocular drug delivery system, to create treatments that can provide continuous therapeutic effects for extended periods.
EyePoint Pharmaceuticals has made significant strides in the field of retinal disease treatments. Its lead product candidate, DURAVYU™ (previously known as EYP-1901), is an investigational treatment for VEGF-mediated retinal diseases. This product combines vorolanib, a selective tyrosine kinase inhibitor, with the Durasert® technology to offer sustained delivery and improved patient outcomes. DURAVYU™ is currently undergoing clinical trials for conditions such as wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR).
The company also has several other promising candidates in its pipeline, including EYP-2301, a TIE-2 agonist, and razuprotafib, formulated with Durasert® technology to potentially enhance treatment outcomes for serious retinal diseases.
EyePoint’s innovative approach extends beyond product development to strategic partnerships and collaborations. The company has secured exclusive licenses for vorolanib from Equinox Sciences for all ophthalmic uses outside of China, Macao, Hong Kong, and Taiwan. Additionally, EyePoint has FDA-approved products such as RETISERT® and YUTIQ® that are based on its proprietary drug delivery technology.
Financially, EyePoint Pharmaceuticals has shown a solid performance with total net revenue of $46.0 million for the year ended December 31, 2023, compared to $41.4 million for the previous year. This growth is driven primarily by revenues from royalties and collaborations. The company has also strengthened its financial position with $331.1 million in cash, cash equivalents, and marketable securities as of December 31, 2023.
EyePoint is dedicated to driving innovation in ophthalmology and improving the quality of life for patients with serious eye conditions. With a focus on advancing its robust pipeline through clinical development, EyePoint Pharmaceuticals continues to make headway in addressing unmet medical needs in retinal diseases.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced that the American Medical Association accepted a new Category III CPT code (0X78T) for drug administration in the eye, effective January 1, 2022. This code provides a reimbursement pathway for DEXYCU, the first FDA-approved sustained-release intracameral steroid for postoperative inflammation treatment. The approval is seen as a significant step toward increased adoption of DEXYCU, enhancing its market presence and financial prospects.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced its inclusion in the small-cap Russell 2000® Index and the broader Russell 3000® Index, effective June 28, 2021. This addition reflects the company’s position among approximately 2,000 smaller companies based on market capitalization.
The Russell indexes are critical benchmarks for investment strategies, managing $10.6 trillion in assets. EyePoint focuses on therapeutics for serious eye disorders, leveraging its proprietary Durasert® technology and two commercial products, YUTIQ® and DEXYCU®.
EyePoint Pharmaceuticals (NASDAQ: EYPT) will have CEO Nancy Lurker speak at the Jefferies Healthcare Conference on June 2, 2021, at 9:30 a.m. ET. The session will explore the company's commitment to developing therapies for serious eye disorders, including innovations like EYP-1901, a treatment for wet age-related macular degeneration. Attendees can access a live webcast and a 90-day archive via EyePoint's website. The company also markets YUTIQ and DEXYCU for eye disorder treatments.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced successful enrollment completion for its Phase 1 trial of EYP-1901, a potential twice-yearly treatment for wet age-related macular degeneration (wet AMD). The trial includes dose escalation for patients previously responsive to anti-VEGF therapies. Interim data is expected in Q4 2021. EYP-1901 employs EyePoint’s Durasert technology for sustained delivery, potentially improving treatment outcomes for patients. The company aims to explore additional applications for EYP-1901, including diabetic retinopathy.
EyePoint Pharmaceuticals (EYPT) reported a productive first quarter of 2021, achieving net product revenues of $6.8 million, a 45% increase from $4.7 million in Q1 2020. The company completed a $115.1 million follow-on financing, enhancing its development pipeline. The Phase 1 DAVIO study for EYP-1901 targeting wet AMD is on track for initial data in Q4 2021. However, total net revenue declined slightly to $7.3 million from $7.5 million year-over-year. The net loss was $12.3 million, or ($0.50) per share, an improvement from a loss of $13.2 million in the same quarter last year.
EyePoint Pharmaceuticals (NASDAQ: EYPT) is set to host a conference call on May 5, 2021, at 8:30 a.m. ET to announce its Q1 2021 financial results and discuss corporate developments. The call will be accessible via phone and a live webcast on the company’s website. EyePoint focuses on therapeutics for serious eye disorders, utilizing its Durasert® technology for sustained drug delivery. Its commercial products include YUTIQ® for chronic uveitis and DEXYCU® for postoperative inflammation.
EyePoint Pharmaceuticals (EYPT) reported financial results for Q4 and the full year ended December 31, 2020. Total net revenue increased to $34.4 million, up from $20.4 million in 2019. Net product revenue for the year was $20.8 million, compared to $16.8 million in the prior year. However, the company incurred a net loss of $45.4 million, or $3.54 per share. EyePoint raised $115.1 million through a public stock offering in February 2021, strengthening their financial position. They also highlighted progress in their EYP-1901 clinical trial for wet AMD.
EyePoint Pharmaceuticals (NASDAQ: EYPT) is set to present at two upcoming virtual conferences in March 2021. The first event is the Cowen Healthcare Conference on March 3, from 2:40-3:10 PM Eastern Time, featuring a fireside chat. The second event is the H.C. Wainwright Global Life Sciences Conference on March 9, at 7:00 AM Eastern Time, with a formal presentation. Investors can access a live webcast and archived replay on the company’s website for 90 days post-event. EyePoint focuses on therapeutics for serious eye disorders, leveraging Durasert® technology and offering products like YUTIQ® and DEXYCU®.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) will hold a conference call on March 4, 2021, at 8:30 a.m. ET to discuss its full year 2020 financial results and recent business highlights. The call can be accessed by dialing (877)-312-7507 or (631)-813-4828 with conference ID 1261618. The company focuses on developing therapeutics for serious eye disorders, leveraging Durasert® technology for sustained drug delivery. EyePoint has two commercial products: YUTIQ® and DEXYCU®.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has completed a public offering of 10,465,000 shares at $11.00 per share, raising approximately $115.1 million, post-underwriting expenses. The offering included an option for underwriters to purchase an additional 1,365,000 shares. The net proceeds will support the advancement of EYP-1901 for treating wet AMD, pipeline, commercial programs, and general corporate purposes. This was conducted under a previously filed shelf registration statement with the SEC.
FAQ
What is the current stock price of EyePoint Pharmaceuticals (EYPT)?
What is the market cap of EyePoint Pharmaceuticals (EYPT)?
What does EyePoint Pharmaceuticals, Inc. (EYPT) specialize in?
What is DURAVYU™?
Where is EyePoint Pharmaceuticals headquartered?
What are the key products in EyePoint's pipeline?
How did EyePoint Pharmaceuticals perform financially in 2023?
What is the Durasert® technology?
Has EyePoint Pharmaceuticals received FDA approval for any products?
What are the geographical operational footprints of EyePoint Pharmaceuticals?
What is EyePoint's strategy for future growth?
How does EyePoint Pharmaceuticals generate revenue?
